Position of the Transparency Council – Fasenra (benralizumab)

At its meeting on 3 March 2025, the Transparency Council adopted position No. 29/2025 on the evaluation of the drug Fasenra (benralizumab) as part of the drug program “Treatment of patients with systemic vasculitis (ICD-10: M31.3, M31.5, M31.6, M31.7, M31.8)”

Publication of the position >>